Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Inappropriate schedule of vaccine administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in 2018). In JAN-2025, the patient received the 2nd dose of Shingrix. In JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate schedule of vaccine administered). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date:25-MAR-2025 The reporter was a Pharmacist that was calling in regards to her mother who had taken the first Shingrix vaccine in 2018 and then, received her 2nd vaccine 2 months ago. Daughter did not give me any further information in regards to her mother. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.; Sender's Comments: US-GSK-US2025036051:same reporter